PLAY PODCASTS
A Second Chance for an ALS Drug... Dr. Ari Azhir, Founder & CEO, Neuvivo
Episode 25008

A Second Chance for an ALS Drug... Dr. Ari Azhir, Founder & CEO, Neuvivo

BioTech Nation ... with Dr. Moira Gunn · Moira Gunn

February 26, 202517m 47s

Audio is streamed directly from the publisher (media.transistor.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.

Show Notes

This week on Biotech Nation, Dr. Ari Azhir, Founder and CEO of Neuvivo, shares the incredible journey of an ALS drug that was once abandoned, but is now making its way toward FDA approval. After two failed phase two trials, the drug was left behind until Dr. Azhir and her team discovered a crucial mistake in the trial data. Now with new insights and groundbreaking survival results, Neuvivo is giving hope to ALS patients and exploring its potential for other neurodegenerative diseases like Huntington’s and Alzheimer’s. 

Topics

ALSneurodegenerative diseaseNeuvivoDr. Ari AzhirbiotechFDA approvalclinical trialsphase two trialsHuntington’s diseaseAlzheimer’s diseasevascular dementiaimmune systemdrug developmentorphan drugALS treatmentneurological disordersbiotech innovationpharmaceutical researchmuscle functionsurvival benefitmedical breakthroughbiotech entrepreneurshipregenerative medicinescientific discoverydrug repurposingbiotech investmenthealthcare advancementsFDA submissionpatient survivalneurosciencebiotechnology industrydrug approval process